At a Glance CRISPR/Cas9 gene editing shows much promise therapeutically, and since its debut, there’s been lots of research into developing and using the technique

But although SpCas9 and SaCas9 are currently the most commonly used Cas9 orthologues for CRISPR/Cas9 gene editing, each has limitations for gene therapy approaches

According to recently published research, a team from South Korea might have found a promising alternative – CjCas9

SeeokJong Kim and Sung Wook Park, co-authors on the paper, tell us about their work and what’s next

There is little doubt that the future of medicine is gene editing. But right now, the focus is on figuring out how to get there as safely and effectively as possible. An approach at the forefront of our gene-editing endeavors is CRISPR (clustered regularly interspaced short palindromic repeats)/Cas – and since its debut in 2013 (1)(2)(3), research has been booming.